API Granisetron

Granisetron More Info

Granisetron is a commonly used serotonin 5-HT₃ receptor antagonist, mainly prescribed to prevent and treat nausea and vomiting—common side effects of cancer chemotherapy, radiation therapy, and certain surgical procedures. Its core mechanism is blocking the action of serotonin (a chemical messenger) in the brain and digestive tract, as these areas are key triggers for nausea and vomiting reactions.

1. Basic Information

Generic Name: Granisetron

CAS Number: 107007-99-8

Molecular Formula: C₁₈H₂₄N₄O

Mechanism of Action: It selectively blocks 5-HT₃ receptors in the central nervous system (CNS) and peripheral nervous system (e.g., the gut). By inhibiting the transmission of "vomiting reflex" signals through these receptors, it reduces or stops nausea and vomiting.

Drug Class: Antiemetic (anti-nausea/vomiting drug); specifically classified as a 5-HT₃ receptor antagonist.

2. Key Uses

Granisetron is mainly used in three clinical scenarios, with dosages and administration routes adjusted according to specific needs:

Chemotherapy-induced nausea and vomiting (CINV): It is used for both "acute" (occurring within 24 hours after chemotherapy) and "delayed" (occurring 24–120 hours after chemotherapy) nausea/vomiting. The choice of oral tablets, oral solution, or injection depends on the patient’s ability to take oral medications and the severity of expected symptoms.

Radiation-induced nausea and vomiting (RINV): It is often prescribed for patients receiving radiation therapy to the abdomen, pelvis, or other areas that are prone to triggering nausea/vomiting. It helps reduce discomfort during and after radiation sessions.

Postoperative nausea and vomiting (PONV): It is usually given as an injection before or after surgery to prevent nausea and vomiting that may occur in the recovery period, especially for patients with a higher risk of PONV (e.g., those who have had PONV before, or are undergoing certain types of surgery like gynecological or abdominal surgery).

3. Common Administration Forms

Oral formulations: Including tablets (common strengths like 1mg) and oral solution (for patients who have difficulty swallowing, such as children or elderly patients).

Injectable formulations: Intravenous (IV) injection or infusion is the main form for clinical scenarios where oral intake is not possible (e.g., during chemotherapy sessions, or post-surgery when patients cannot eat/drink immediately).

Transdermal patch: A less common but convenient form—applied to the skin, it releases granisetron slowly over several days, suitable for long-term prevention (e.g., continuous prevention of delayed CINV).

4. Important Safety Notes

Common side effects: Mild and temporary reactions are common, such as headache, dizziness, constipation, or mild fatigue. These symptoms usually improve on their own without special treatment.

Contraindications: It is not recommended for patients with a known hypersensitivity to granisetron or other 5-HT₃ receptor antagonists (e.g., ondansetron), as it may trigger allergic reactions like rash, difficulty breathing, or swelling.

Drug interactions: It may interact with certain medications (e.g., some antidepressants that affect serotonin levels, like SSRIs). Patients should inform doctors of all current medications to avoid potential risks (e.g., serotonin syndrome, a rare but serious condition).

Special populations: Pregnant or breastfeeding women should use it only if prescribed by a doctor (after weighing the benefits and risks). For elderly patients or those with liver/kidney dysfunction, dosage adjustments may be needed based on organ function.